Efficacy and safety of intravenous fosphenytoin for patients with acute herpes zoster‐associated pain: A placebo‐controlled randomized trial

• Published in: Journal of dermatology Vol. 51; no. 2; pp. 234 - 242
• Main Authors: Iseki, Masako, Yamamoto, Takenobu, Ogawa, Youichi, Majima, Yuta, Abe, Yoichiro, Watanabe, Daisuke, Amaya, Fumimasa, Hasegawa, Toshio, Inafuku, Kazuhiro, Kosugi, Toshifumi, Nomura, Yukiko, Deguchi, Tokiko, Hamada, Toshihisa, Shimizu, Kenji, Arai, Saori, Takahashi, Morito, Hamada, Izumi, Ishikawa, Yuko, Kawashima, Makoto
• Format: Journal Article
• Language: English
• Published: England Wiley Subscription Services, Inc 01.02.2024; John Wiley and Sons Inc
• Subjects: Adult; Age; Aged; Analgesics; Analgesics, Non-Narcotic - pharmacology; Coronaviruses; COVID-19; Dosage; Double-Blind Method; Herpes viruses; Herpes zoster; Herpes Zoster - complications; Herpes Zoster - drug therapy; Herpesvirus 3, Human; Humans; Intravenous administration; Middle Aged; Original; Pain; Pain - drug therapy; Pain - etiology; Patients; Phenytoin; Phenytoin - adverse effects; Placebos; postherpetic neuralgia; prodrugs; Safety; Young Adult; postherpetic neuralgia; herpes zoster; phenytoin; prodrugs; safety
• ISSN: 0385-2407; 1346-8138; 1346-8138
• DOI: 10.1111/1346-8138.17054

Acute zoster‐associated pain develops in most patients with herpes zoster. Nonopioid analgesics are usually used to treat acute zoster‐associated pain but are frequently ineffective. We administered intravenous fosphenytoin, the prodrug of phenytoin, to patients with acute zoster‐associated pain to examine its analgesic efficacy and safety. At 13 medical institutions in Japan, we conducted a phase II, double‐blind, placebo‐controlled, randomized trial of intravenous fosphenytoin in Japanese inpatients with acute zoster‐associated pain for whom nonopioid analgesics had shown an insufficient analgesic effect. The patients were randomly assigned (1:1:1) to receive a single intravenous dose of fosphenytoin at 18 mg/kg (high dose), a single intravenous dose of fosphenytoin at 12 mg/kg (low dose), or placebo. The primary endpoint was the mean change per hour (slope) in the numerical rating scale score from the baseline score until 120 min after dosing. Seventeen patients were randomly assigned to the low‐dose fosphenytoin group (n = 6, median age 62.5 years, range 39–75 years), high‐dose fosphenytoin group (n = 5, median age 69.0 years, range 22–75 years), and placebo group (n = 5, median age 52.0 years, range 38–72 years). One patient was excluded because of investigational drug dilution failure. This study was discontinued because of the influences of coronavirus disease 2019. The slope was significantly lower in the high‐ and low‐dose fosphenytoin groups than in the placebo group (P < 0.001 and P = 0.016, respectively). Responsiveness to intravenous fosphenytoin (≥2‐point reduction in the numerical rating scale score from baseline to 120 min after dosing) was inferred at plasma total phenytoin concentrations of 10–15 μg/mL. Treatment‐emergent adverse events caused no safety concerns in the clinical setting and intravenous fosphenytoin was well tolerated. Intravenous fosphenytoin appears to be an effective and promising alternative treatment for acute zoster‐associated pain. Trial Registration: ClinicalTrials.gov NCT04139330.